Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies ...

Harbour BioMed, Insilico Medicine enter strategic collaboration to advance AI-driven antibody discovery and development: Cambridge, Massachusetts Saturday, February 22, 2025, 14:0 ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and ...

February 20, 2025, Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Chromatin-associated RNAs play various roles in gene regulation and genome organization, yet they remain challenging to interrogate. Here the authors report a targeted DNA-associated RNA and RNA ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.